- Trials with a EudraCT protocol (1,721)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,721 result(s) found for: Genetic disorders.
Displaying page 1 of 87.
EudraCT Number: 2005-004008-36 | Sponsor Protocol Number: ANAK-01 | Start Date*: 2005-10-27 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis | |||||||||||||
Medical condition: CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003588-85 | Sponsor Protocol Number: PSYCHIC | Start Date*: 2022-01-11 |
Sponsor Name:UCLouvain | ||
Full Title: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ? | ||
Medical condition: Schizophrenia, schizoaffective disorders, psychosis not otherwise specified, and dellusional disorders | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001888-39 | Sponsor Protocol Number: PGX-HT | Start Date*: 2016-01-28 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: PHARMACOGENOMICS HYPERTENSION : A NEW APPROACH FOR PERSONALIZED MEDICINE ( PGX - HT ) | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005032-30 | Sponsor Protocol Number: FLT201-01 | Start Date*: 2023-03-13 | ||||||||||||||||
Sponsor Name:Freeline Therapeutics Limited | ||||||||||||||||||
Full Title: A Phase 1/2, open-label, safety, tolerability and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 (Galileo-1) | ||||||||||||||||||
Medical condition: Type 1 Gaucher Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005275-42 | Sponsor Protocol Number: 1140 | Start Date*: 2005-03-21 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | |||||||||||||
Full Title: Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta | |||||||||||||
Medical condition: Osteogenesis Imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001678-40 | Sponsor Protocol Number: CACZ885N2301E2 | Start Date*: 2017-05-15 | |||||||||||
Sponsor Name:Novartis pharma AG | |||||||||||||
Full Title: An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes | |||||||||||||
Medical condition: Three disease of periodic fever syndromes, TNF receptor Associated Periodic Syndrome (TRAPS), Hyper IgDSyndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002267-25 | Sponsor Protocol Number: SEOTP-2018 | Start Date*: 2018-07-18 |
Sponsor Name:Fakultní nemocnice Brno | ||
Full Title: SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE | ||
Medical condition: Psychoses | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003907-16 | Sponsor Protocol Number: SPIMD-301 | Start Date*: 2022-03-02 | |||||||||||||||||||||
Sponsor Name:Stealth BioTherapeutics Inc. | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondr... | |||||||||||||||||||||||
Medical condition: Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) NO (Completed) ES (Completed) IT (Completed) NL (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000368-27 | Sponsor Protocol Number: MAN-ALG-18-001 | Start Date*: 2018-10-22 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: ND | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002856-33 | Sponsor Protocol Number: ALN-TTRSC-002 | Start Date*: 2013-11-15 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis | |||||||||||||
Medical condition: Transthyretin (TTR) Cardiac Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000672-28 | Sponsor Protocol Number: VX10-770-107 | Start Date*: 2017-03-27 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FE... | |||||||||||||
Medical condition: cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001004-33 | Sponsor Protocol Number: VX15-809-115 | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for t... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001229-34 | Sponsor Protocol Number: ALN-TTRSC-003 | Start Date*: 2014-08-01 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis Who Have Previo... | |||||||||||||
Medical condition: Transthyretin (TTR) Cardiac Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001309-34 | Sponsor Protocol Number: VX14-809-106 | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000673-37 | Sponsor Protocol Number: VX12-770-113 | Start Date*: 2017-03-27 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 ≥40% Predicted | |||||||||||||
Medical condition: cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004996-33 | Sponsor Protocol Number: VX15-809-114 | Start Date*: 2017-05-03 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incoporated | |||||||||||||
Full Title: A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallelgroup, Pilot Study of Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del-CFTR Mutation | |||||||||||||
Medical condition: Cystic fibrosis subjects Homozygous for the F508del-CFTR Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001118-32 | Sponsor Protocol Number: EP06-401 | Start Date*: 2011-05-25 | |||||||||||||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||||||||||||
Full Title: Twelve-month study on the immunogenicity, safety, and efficacy of Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia | |||||||||||||||||||||||
Medical condition: Severe chronic neutropenia (i.e. congenital neutropenia, cyclic neutropenia and chronic idiopathic neutropenia) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003250-23 | Sponsor Protocol Number: 78162.018.21 | Start Date*: 2025-01-24 | ||||||||||||||||
Sponsor Name:Amsterdam UMC | ||||||||||||||||||
Full Title: Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X Syndrome: an N-of-1 series | ||||||||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC), Sanfilippo syndrome, Fragile X syndrome (FXS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000387-14 | Sponsor Protocol Number: RM-493-014 | Start Date*: 2017-05-24 |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity | ||
Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003313-42 | Sponsor Protocol Number: AGO-TEA | Start Date*: 2012-03-29 |
Sponsor Name:Hospital General Universitario de Alicante | ||
Full Title: Efficacy of agomelatine on sleep disturbance in Autism Spectrum Disorder (ASD) | ||
Medical condition: The treatment of sleep disorders in patients with autism spectrum disorders (ASD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
